Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Application Number	Priority Date	Filing Date	Title
US33117710P	2010-05-04	2010-05-04

Publication Number	Publication Date
SG10201911345WAtrue SG10201911345WA (en)	2020-01-30

Family

ID=44902080

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
SG10201911345WASG10201911345WA (en)	2010-05-04	2011-05-04	Antibodies that bind csf1r
SG2012079133ASG185035A1 (en)	2010-05-04	2011-05-04	Antibodies that bind csf1r
SG10201604798SASG10201604798SA (en)	2010-05-04	2011-05-04	Antibodies that bind csf1r

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
SG2012079133ASG185035A1 (en)	2010-05-04	2011-05-04	Antibodies that bind csf1r
SG10201604798SASG10201604798SA (en)	2010-05-04	2011-05-04	Antibodies that bind csf1r

Country Status (27)

Country	Link
US (8)	US8206715B2 (en)
EP (3)	EP3357510B1 (en)
JP (6)	JP6008842B2 (en)
KR (3)	KR20200044999A (en)
CN (4)	CN106977603B (en)
AU (4)	AU2011248083B2 (en)
BR (1)	BR112012027994B1 (en)
CA (1)	CA2797399C (en)
CY (1)	CY1121102T1 (en)
DK (1)	DK2566517T3 (en)
EA (1)	EA036336B1 (en)
ES (2)	ES2820517T3 (en)
HR (1)	HRP20190047T1 (en)
HU (1)	HUE042898T2 (en)
IL (3)	IL222629B (en)
LT (1)	LT2566517T (en)
MX (3)	MX355418B (en)
NZ (3)	NZ712765A (en)
PL (1)	PL2566517T3 (en)
PT (1)	PT2566517T (en)
RS (1)	RS58211B1 (en)
SG (3)	SG10201911345WA (en)
SI (1)	SI2566517T1 (en)
SM (1)	SMT201900074T1 (en)
TR (1)	TR201900368T4 (en)
TW (5)	TWI713942B (en)
WO (1)	WO2011140249A2 (en)

Families Citing this family (296)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2007145840A2 (en)	2006-06-13	2007-12-21	Oncomed Pharmaceuticals, Inc.	Compositions and methods for diagnosing and treating cancer
EP2125887A4 (en)	2007-01-24	2010-11-10	Oncomed Pharm Inc	Compositions and methods for diagnosing and treating cancer
CN102316897B (en)	2008-07-08	2014-11-05	昂考梅德药品有限公司	Notch binders and antagonists and methods of use thereof
RU2565541C2 (en)	2009-12-10	2015-10-20	Ф.Хоффманн-Ля Рош Аг	Antibodies primarily binding to extracellular domain 4 of human csf-1r, and using them
WO2017120461A1 (en)	2016-01-08	2017-07-13	The Board Of Trustees Of The Leland Stanford Junior University	Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same
US10487148B2 (en)	2010-01-28	2019-11-26	The Board Of Trustees Of The Leland Stanford Junior University	Methods and compositions for treating aging-associated impairments
US20160208011A1 (en)	2010-01-28	2016-07-21	The Board Of Trustees Of The Leland Stanford Junior University	Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same
BR112012020372A8 (en)	2010-03-05	2018-01-02	Hoffmann La Roche	human csf-1r binding antibody, pharmaceutical composition, nucleic acid, expression vectors, host cell and method for producing a recombinant antibody
KR101647871B1 (en)	2010-03-05	2016-08-11	에프. 호프만-라 로슈 아게	Antibodies against human csf-1r and uses thereof
SG10201911345WA (en)	2010-05-04	2020-01-30	Five Prime Therapeutics Inc	Antibodies that bind csf1r
US9161968B2 (en)	2011-04-08	2015-10-20	The Board Of Trustees Of The Leland Stanford Junior University	Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists
WO2013011021A1 (en)	2011-07-18	2013-01-24	The University Of Melbourne	Use of c-fms antagonists
MX360741B (en)	2011-10-28	2018-11-14	Teva Pharmaceuticals Australia Pty Ltd	Polypeptide constructs and uses thereof.
US10023643B2 (en)	2011-12-15	2018-07-17	Hoffmann-La Roche Inc.	Antibodies against human CSF-1R and uses thereof
EP2812355A4 (en)*	2012-02-06	2016-03-02	Hoffmann La Roche	COMPOSITIONS AND METHODS OF USING CSF1R INHIBITORS
US9708601B2 (en)*	2012-04-26	2017-07-18	Vaccinex, Inc.	Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
US20130302322A1 (en)*	2012-05-11	2013-11-14	Five Prime Therapeutics, Inc.	Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
HK1208233A1 (en)	2012-05-11	2016-02-26	戊瑞治疗有限公司	Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
AU2015264860B2 (en)*	2012-05-11	2017-03-02	Five Prime Therapeutics, Inc.	Method of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)
US20140079699A1 (en)*	2012-08-31	2014-03-20	Five Prime Therapeutics, Inc.	Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
PL2905335T3 (en)*	2012-10-03	2018-06-29	Chiome Bioscience Inc.	Anti-human dlk-1 antibody having anti-tumor activity in vivo
JP2016510977A (en)*	2013-02-28	2016-04-14	ユニバーシティコートオブザユニバーシティオブエディンバラＵｎｉｖｅｒｓｉｔｙＣｏｕｒｔＯｆＴｈｅＵｎｉｖｅｒｓｉｔｙＯｆＥｄｉｎｂｕｒｇｈ	CSF1 therapeutic agent
SG11201507871XA (en)	2013-04-12	2015-10-29	Morphosys Ag	Antibodies targeting m-csf
AR095882A1 (en)	2013-04-22	2015-11-18	Hoffmann La Roche	ANTIBODY COMBINATION THERAPY AGAINST HUMAN CSF-1R WITH A TLR9 AGONIST
GB201315487D0 (en)*	2013-08-30	2013-10-16	Ucb Pharma Sa	Antibodies
AR097584A1 (en)*	2013-09-12	2016-03-23	Hoffmann La Roche	ANTIBODY COMBINATION THERAPY AGAINST HUMAN CSF-1R AND ANTIBODIES AGAINST HUMAN PD-L1
US10905779B2 (en)	2013-12-09	2021-02-02	The Board Of Trustees Of The Leland Stanford Junior University	Methods for screening human blood products comprising plasma using immunocompromised rodent models
WO2015088915A1 (en)	2013-12-09	2015-06-18	The Board Of Trustees Of The Leland Stanford Junior University	Methods and compositions for treating aging-associated conditions
CN108558871B (en)	2013-12-24	2022-02-18	百时美施贵宝公司	Tricyclic compounds as anticancer agents
WO2015153997A2 (en)*	2014-04-04	2015-10-08	Oncomed Pharmaceuticals, Inc.	Notch3 antibodies and uses thereof
EP3151921B1 (en)	2014-06-06	2019-08-28	Bristol-Myers Squibb Company	Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
EP3151820A4 (en)	2014-06-06	2017-11-22	Flexus Biosciences, Inc.	Immunoregulatory agents
KR20230086809A (en)	2014-06-23	2023-06-15	파이브 프라임 테라퓨틱스, 인크.	Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
SMT202100301T1 (en)	2014-10-29	2021-07-12	Bicyclerd Ltd	Bicyclic peptide ligands specific for mt1-mmp
EA036261B1 (en)*	2014-10-29	2020-10-20	Файв Прайм Терапьютикс, Инк.	Combination therapy for cancer
JP2017538678A (en)	2014-11-05	2017-12-28	フレクサス・バイオサイエンシーズ・インコーポレイテッドＦｌｅｘｕｓＢｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ．	Immunomodulator
UY36391A (en)	2014-11-05	2016-06-01	Flexus Biosciences Inc	MODULATING COMPOUNDS OF INDOLAMINE ENZYME 2,3-DIOXYGENASE (IDO1), ITS SYNTHESIS METHODS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
UY36390A (en)	2014-11-05	2016-06-01	Flexus Biosciences Inc	MODULATING COMPOUNDS OF INDOLAMINE ENZYME 2,3-DIOXYGENASE (IDO), ITS SYNTHESIS METHODS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
CA2968357A1 (en)	2014-11-21	2016-05-26	Bristol-Myers Squibb Company	Antibodies against cd73 and uses thereof
AR103232A1 (en)	2014-12-22	2017-04-26	Bristol Myers Squibb Co	TGFbR ANTAGONISTS
BR112017013111A2 (en)*	2014-12-22	2018-05-15	Five Prime Therapeutics Inc	methods of treating a disorder and treating synovitis, use of an antibody and antibody
KR102644115B1 (en)	2014-12-23	2024-03-05	브리스톨-마이어스 스큅 컴퍼니	Antibodies to tigit
US10983128B2 (en)	2015-02-05	2021-04-20	Bristol-Myers Squibb Company	CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy
WO2016128318A1 (en)*	2015-02-09	2016-08-18	Ucb Biopharma Sprl	Pharmaceutical formulation
JP6836998B2 (en)	2015-03-02	2021-03-03	ライジェルファーマシューティカルズ，インコーポレイテッド	TGF-β inhibitor
CN108093636A (en)	2015-04-03	2018-05-29	百时美施贵宝公司	Indoleamine 2, 3-dioxygenase inhibitors for the treatment of cancer
TW201642897A (en)	2015-04-08	2016-12-16	Ｆ星生物科技有限公司	HER2 binding agent therapies
SI3283527T1 (en)	2015-04-13	2021-04-30	Five Prime Therapeutics, Inc.	Combination therapy against cancer
US10683290B2 (en)	2015-05-11	2020-06-16	Bristol-Myers Squibb Company	Tricyclic compounds as anticancer agents
US9725449B2 (en)	2015-05-12	2017-08-08	Bristol-Myers Squibb Company	Tricyclic compounds as anticancer agents
WO2016183115A1 (en)	2015-05-12	2016-11-17	Bristol-Myers Squibb Company	5h-pyrido[3,2-b]indole compounds as anticancer agents
WO2016187594A1 (en)	2015-05-21	2016-11-24	Harpoon Therapeutics, Inc.	Trispecific binding proteins and methods of use
MX2017014782A (en)*	2015-05-27	2018-02-15	Ucb Biopharma Sprl	Method for the treatment of neurological disease.
TN2019000101A1 (en)	2015-05-29	2020-07-15	Bristol Myers Squibb Co	Antibodies against ox40 and uses thereof.
EP3307296B1 (en)	2015-06-15	2021-10-20	The Board of Trustees of the Leland Stanford Junior University	Timp2 for use in treating aging-associated conditions
JP6621252B2 (en)*	2015-06-17	2019-12-18	国立大学法人北海道大学	Treatment resistance reducing agent for treatment resistant cancer
EP3313886A1 (en)	2015-06-29	2018-05-02	The Rockefeller University	Antibodies to cd40 with enhanced agonist activity
CN108137597A (en)	2015-07-28	2018-06-08	百时美施贵宝公司	Tgf beta receptor antagonists
CN108349976A (en)	2015-08-25	2018-07-31	百时美施贵宝公司	TGF β receptor antagonists
MA42843A (en)*	2015-09-16	2018-07-25	Ablexis Llc	ANTI-CD115 ANTIBODY
ES2809125T3 (en)	2015-09-23	2021-03-03	Bristol Myers Squibb Co	Glypican-3 binding fibronectin-based scaffold molecules
AU2016356780A1 (en)	2015-11-19	2018-06-28	Bristol-Myers Squibb Company	Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
CN108602829A (en)	2015-12-15	2018-09-28	百时美施贵宝公司	Cxcr4 receptor antagonists
IL295230A (en)	2016-03-04	2022-10-01	Bristol Myers Squibb Co	Combination therapy with anti-cd73 antibodies
KR102414558B1 (en)	2016-04-18	2022-06-29	셀덱스 쎄라퓨틱스, 인크.	Agonistic antibodies that bind to human CD40 and uses thereof
ES3037703T3 (en)	2016-04-28	2025-10-06	Alkahest Inc	Blood plasma and plasma fractions as therapy for tumor growth and progression
EP3452030A4 (en)	2016-05-04	2019-11-13	Bristol-Myers Squibb Company	Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US10544099B2 (en)	2016-05-04	2020-01-28	Bristol-Myers Squibb Company	Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
KR20190004742A (en)	2016-05-04	2019-01-14	브리스톨-마이어스 스큅 컴퍼니	Inhibitors of indoleamine 2,3-dioxygenase and methods of use thereof
US10323004B2 (en)	2016-05-04	2019-06-18	Bristol-Myers Squibb Company	Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
CN109348714A (en)	2016-05-04	2019-02-15	百时美施贵宝公司	The inhibitor and its application method of indole amine 2,3-dioxygenase
US11623958B2 (en)	2016-05-20	2023-04-11	Harpoon Therapeutics, Inc.	Single chain variable fragment CD3 binding proteins
WO2017210335A1 (en)	2016-06-01	2017-12-07	Bristol-Myers Squibb Company	Imaging methods using 18f-radiolabeled biologics
WO2017220989A1 (en)	2016-06-20	2017-12-28	Kymab Limited	Anti-pd-l1 and il-2 cytokines
MY200602A (en)	2016-07-14	2024-01-04	Bristol Myers Squibb Co	Antibodies against tim3 and uses thereof
US20190292179A1 (en)	2016-07-21	2019-09-26	Bristol-Myers Squibb Company	TGF Beta RECEPTOR ANTAGONISTS
EP3494131B1 (en)	2016-08-02	2024-09-18	Vaccinex, Inc.	Improved methods for producing polynucleotide libraries in vaccinia virus/eukaryotic cells
US10525107B2 (en)	2016-08-18	2020-01-07	Alkahest, Inc.	Blood plasma fractions as a treatment for aging-associated cognitive disorders
CN109790220A (en)	2016-08-25	2019-05-21	豪夫迈·罗氏有限公司	Intermittent dosing of anti-CSF-1R antibodies in combination with macrophage activators
US11337970B2 (en)	2016-08-26	2022-05-24	Bristol-Myers Squibb Company	Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US11351164B2 (en)	2016-08-26	2022-06-07	Bristol-Myers Squibb Company	Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US10660909B2 (en)	2016-11-17	2020-05-26	Syntrix Biosystems Inc.	Method for treating cancer using chemokine antagonists
MA47106A (en)	2016-12-21	2019-10-30	Amgen Inc	ANTI-TNF ALPHA ANTIBODY FORMULATIONS
CN110072553B (en)	2016-12-22	2023-09-15	豪夫迈·罗氏有限公司	Treatment of tumors with anti-CSF-1R antibodies in combination with anti-PD-L1 antibodies after failure of anti-PD-L1/PD 1 treatment
US10961239B2 (en)	2017-01-05	2021-03-30	Bristol-Myers Squibb Company	TGF beta receptor antagonists
EP3570844B1 (en)	2017-01-20	2023-09-06	Arcus Biosciences, Inc.	Azolopyrimidine for the treatment of cancer-related disorders
JP2017125040A (en)*	2017-02-28	2017-07-20	ファイブプライムセラピューティックスインコーポレイテッド	Methods for treating conditions using antibodies that bind colony stimulating factor 1 receptor (csf1r)
EA201992248A1 (en)	2017-03-23	2020-02-06	Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания	ANTI-C5a-ANTIBODIES AND THEIR APPLICATION
WO2018183366A1 (en)	2017-03-28	2018-10-04	Syndax Pharmaceuticals, Inc.	Combination therapies of csf-1r or csf-1 antibodies and a t-cell engaging therapy
WO2018183608A1 (en)	2017-03-31	2018-10-04	Five Prime Therapeutics, Inc.	Combination therapy for cancer using anti-gitr antibodies
TWI788340B (en)	2017-04-07	2023-01-01	美商必治妥美雅史谷比公司	Anti-icos agonist antibodies and uses thereof
AU2018256406A1 (en)	2017-04-19	2019-10-17	Marengo Therapeutics, Inc.	Multispecific molecules and uses thereof
SG11201909710XA (en)	2017-04-21	2019-11-28	Kyn Therapeutics	Indole ahr inhibitors and uses thereof
US11040068B2 (en)	2017-04-26	2021-06-22	Alkahest, Inc.	Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
EP4299129A3 (en)	2017-04-26	2024-03-20	Alkahest, Inc.	Dosing regimen for treatment of cognitive impairments with blood plasma products
WO2018209049A1 (en)	2017-05-12	2018-11-15	Bristol-Myers Squibb Company	Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US10543271B2 (en)	2017-05-12	2020-01-28	Harpoon Therapeutics, Inc.	Mesothelin binding proteins
WO2018213377A1 (en)	2017-05-17	2018-11-22	Arcus Biosciences, Inc.	Quinazoline-pyrazole derivatives for the treatment of cancer-related disorders
US12168054B2 (en)	2017-05-19	2024-12-17	Syndax Pharmaceuticals, Inc.	Method of treating cancer using a combination of entinostat and an anti-CSF-1R antibody
EA202090119A1 (en)	2017-06-30	2020-04-21	Бристол-Маерс Сквибб Компани	AMORPHIC AND CRYSTALLINE FORMS OF IDO INHIBITORS
ES2932354T3 (en)	2017-07-28	2023-01-18	Bristol Myers Squibb Co	Cyclic dinucleotides as anticancer agents
JP7670481B2 (en)	2017-08-04	2025-04-30	バイスクルテクス・リミテッド	Bicyclic peptide ligands specific for CD137 - Patent application
KR20200051646A (en)	2017-08-17	2020-05-13	이케나 온콜로지, 인코포레이티드	AHR inhibitors and uses thereof
KR20240138135A (en)	2017-08-25	2024-09-20	파이브 프라임 테라퓨틱스, 인크.	B7-h4 antibodies and methods of use thereof
CN111051328B (en)	2017-08-31	2023-11-03	百时美施贵宝公司	Cyclic dinucleotides as anticancer agents
EP3676277A1 (en)	2017-08-31	2020-07-08	Bristol-Myers Squibb Company	Cyclic dinucleotides as anticancer agents
KR102651946B1 (en)	2017-08-31	2024-03-26	브리스톨-마이어스 스큅 컴퍼니	Cyclic dinucleotides as anticancer agents
CN111479586A (en)	2017-09-13	2020-07-31	戊瑞治疗有限公司	Combination therapy combining anti-CSF 1R and anti-PD-1 antibodies for pancreatic cancer
US11358948B2 (en)	2017-09-22	2022-06-14	Kymera Therapeutics, Inc.	CRBN ligands and uses thereof
MX2020003190A (en)	2017-09-22	2020-11-11	Kymera Therapeutics Inc	Protein degraders and uses thereof.
WO2019074822A1 (en)	2017-10-09	2019-04-18	Bristol-Myers Squibb Company	Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US11203592B2 (en)	2017-10-09	2021-12-21	Bristol-Myers Squibb Company	Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2019074887A1 (en)	2017-10-10	2019-04-18	Bristol-Myers Squibb Company	Cyclic dinucleotides as anticancer agents
WO2019075090A1 (en)	2017-10-10	2019-04-18	Tilos Therapeutics, Inc.	Anti-lap antibodies and uses thereof
IL315737A (en)	2017-10-13	2024-11-01	Harpoon Therapeutics Inc	B cell maturation antigen binding proteins
AU2018347582B2 (en)	2017-10-13	2025-08-28	Harpoon Therapeutics, Inc.	Trispecific proteins and methods of use
JP7254821B2 (en)	2017-10-16	2023-04-10	ブリストル－マイヤーズスクイブカンパニー	Cyclic dinucleotides as anticancer agents
WO2019080889A1 (en)*	2017-10-26	2019-05-02	江苏恒瑞医药股份有限公司	Anti-csf-1r antibody, antigen-binding fragment thereof and pharmaceutical use thereof
JP2021501801A (en)	2017-11-01	2021-01-21	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	Immunostimulatory agonist antibody for use in the treatment of cancer
ES2925450T3 (en)	2017-11-06	2022-10-18	Bristol Myers Squibb Co	Isofuranone compounds useful as HPK1 inhibitors
US20200377571A1 (en)	2017-12-08	2020-12-03	Elstar Therapeutics, Inc.	Multispecific molecules and uses thereof
IL315310A (en)	2017-12-26	2024-10-01	Kymera Therapeutics Inc	IRAK joints and used in them
CN111788227B (en)	2017-12-27	2025-02-25	百时美施贵宝公司	Anti-CD40 antibodies and uses thereof
US11447449B2 (en)	2018-01-05	2022-09-20	Bristol-Myers Squibb Company	Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
EP3737666A4 (en)	2018-01-12	2022-01-05	Kymera Therapeutics, Inc.	Protein degraders and uses thereof
US12129297B2 (en)	2018-01-12	2024-10-29	Bristol-Myers Squibb Company	Antibodies against TIM3 and uses thereof
WO2019140387A1 (en)	2018-01-12	2019-07-18	Kymera Therapeutics, Inc.	Crbn ligands and uses thereof
CN108276495B (en)*	2018-01-24	2022-03-18	博生吉医药科技(苏州)有限公司	NK92MI cell and T cell modified by targeted CSF1R chimeric antigen receptor and preparation method and application thereof
EP3743095A1 (en)	2018-01-26	2020-12-02	Celldex Therapeutics, Inc.	Methods of treating cancer with dendritic cell mobilizing agents
US10793563B2 (en)	2018-01-29	2020-10-06	Merck Patent Gmbh	GCN2 inhibitors and uses thereof
US10988477B2 (en)	2018-01-29	2021-04-27	Merck Patent Gmbh	GCN2 inhibitors and uses thereof
US10519187B2 (en)	2018-02-13	2019-12-31	Bristol-Myers Squibb Company	Cyclic dinucleotides as anticancer agents
CA3091174A1 (en)	2018-02-21	2019-08-29	Five Prime Therapeutics, Inc.	B7-h4 antibody formulations
WO2019165315A1 (en)	2018-02-23	2019-08-29	Syntrix Biosystems Inc.	Method for treating cancer using chemokine antagonists alone or in combination
MX2020008791A (en)	2018-02-23	2021-01-08	Bicycletx Ltd	Multimeric bicyclic peptide ligands.
GB201803226D0 (en)	2018-02-28	2018-04-11	Ultrahuman Twelve Ltd	CSF1R Binding agents
MA52416A (en)	2018-03-02	2021-04-21	Five Prime Therapeutics Inc	B7-H4 ANTIBODIES AND PROCESSES FOR USE
SG11202008113RA (en)	2018-03-05	2020-09-29	Arcus Biosciences Inc	Arginase inhibitors
US11945834B2 (en)	2018-03-08	2024-04-02	Bristol-Myers Squibb Company	Cyclic dinucleotides as anticancer agents
EP3768716A1 (en)	2018-03-21	2021-01-27	Five Prime Therapeutics, Inc.	Antibodies binding to vista at acidic ph
WO2019183551A1 (en)	2018-03-23	2019-09-26	Bristol-Myers Squibb Company	Antibodies against mica and/or micb and uses thereof
EP3774861A1 (en)	2018-03-28	2021-02-17	Bristol-Myers Squibb Company	Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use
BR112020020826A2 (en)	2018-04-12	2021-01-19	Bristol-Myers Squibb Company	ANTICANCER COMBINATION THERAPY WITH CD73 ANTAGONIST ANTIBODY AND PD-1 / PD-L1 AXIS ANTIBODY
AU2019255196A1 (en)	2018-04-16	2020-11-12	Arrys Therapeutics, Inc.	EP4 inhibitors and use thereof
WO2019204604A1 (en)*	2018-04-19	2019-10-24	The Board Of Trustees Of The University Of Illinois	Methods and compositions of inhibiting csf1r for treating allergic inflammation
US12037323B2 (en)	2018-05-03	2024-07-16	Bristol-Myers Squibb Company	Uracil derivatives as Mer-AXL inhibitors
US11180531B2 (en)	2018-06-22	2021-11-23	Bicycletx Limited	Bicyclic peptide ligands specific for Nectin-4
EA202190137A1 (en)	2018-06-27	2021-05-17	Бристол-Маерс Сквибб Компани	NAPHTHYRIDINE COMPOUNDS FOR USE AS T-CELL ACTIVATORS
SMT202300466T1 (en)	2018-06-27	2024-01-10	Bristol Myers Squibb Co	Substituted naphthyridinone compounds useful as t cell activators
US11292792B2 (en)	2018-07-06	2022-04-05	Kymera Therapeutics, Inc.	Tricyclic CRBN ligands and uses thereof
JP7411627B2 (en)	2018-07-09	2024-01-11	ファイヴプライムセラピューティクスインク	Antibody that binds to ILT4
US12091462B2 (en)	2018-07-11	2024-09-17	Five Prime Therapeutics, Inc.	Antibodies binding to vista at acidic pH
CN109053887B (en)*	2018-07-18	2019-07-23	博奥信生物技术（南京）有限公司	A kind of anti-human CSF-1R monoclonal antibody and purposes
CN108948199B (en)*	2018-07-18	2019-06-21	博奥信生物技术（南京）有限公司	Anti-human CSF-1R monoclonal antibody and application thereof
EP3823614A4 (en)	2018-07-18	2022-03-30	Arcus Biosciences, Inc.	SOLID FORMS OF AN AZOLOPYRIMIDINE COMPOUND
CN108948198B (en)*	2018-07-18	2020-09-01	博奥信生物技术（南京）有限公司	Anti-human CSF-1R monoclonal antibody and application thereof
WO2020023356A1 (en)	2018-07-23	2020-01-30	Bristol-Myers Squibb Company	Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2020023355A1 (en)	2018-07-23	2020-01-30	Bristol-Myers Squibb Company	Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US20210317461A1 (en)	2018-08-09	2021-10-14	Verseau Therapeutics, Inc.	Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof
US10959986B2 (en)	2018-08-29	2021-03-30	Bristol-Myers Squibb Company	Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US11253525B2 (en)	2018-08-29	2022-02-22	Bristol-Myers Squibb Company	Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
CN113164419A (en)	2018-09-07	2021-07-23	皮克医疗公司	EIF4E inhibitors and uses thereof
US12195544B2 (en)	2018-09-21	2025-01-14	Harpoon Therapeutics, Inc.	EGFR binding proteins and methods of use
CA3114038A1 (en)	2018-09-25	2020-04-02	Harpoon Therapeutics, Inc.	Dll3 binding proteins and methods of use
US20220242957A1 (en)	2018-09-27	2022-08-04	Marengo Therapeutics, Inc.	Csf1r/ccr2 multispecific antibodies
US11130802B2 (en)	2018-10-10	2021-09-28	Tilos Therapeutics, Inc.	Anti-lap antibody variants
WO2020086469A1 (en)	2018-10-26	2020-04-30	Alkahest, Inc.	Use of plasma and plasma fractions for improvement of pain, wound healing, and postoperative recovery
KR102718333B1 (en)	2018-11-16	2024-10-17	아르커스 바이오사이언시즈 인코포레이티드	Inhibitors of ARG1 and/or ARG2
MY205758A (en)	2018-11-16	2024-11-12	Bristol Myers Squibb Co	Anti-nkg2a antibodies and uses thereof
BR112021010484A2 (en)	2018-11-30	2021-08-24	Kymera Therapeutics, Inc.	Irak degraders and their uses
WO2020123444A1 (en)	2018-12-11	2020-06-18	Celldex Therapeutics, Inc.	Methods of using cd27 antibodies as conditioning treatment for adoptive cell therapy
GB201820288D0 (en)	2018-12-13	2019-01-30	Bicycle Tx Ltd	Bicycle peptide ligaands specific for MT1-MMP
GB201820325D0 (en)	2018-12-13	2019-01-30	Bicyclerd Ltd	Bicyclic peptide ligands specific for psma
WO2020124039A1 (en)	2018-12-13	2020-06-18	Development Center For Biotechnology	Anti-human csf-1r antibody and uses thereof
EP3670659A1 (en)	2018-12-20	2020-06-24	Abivax	Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
JP2019089840A (en)*	2019-02-22	2019-06-13	ファイブプライムセラピューティックスインコーポレイテッド	Method of treating a condition using an antibody that binds colony stimulating factor 1 receptor (CSF1R)
US20220241313A1 (en)	2019-03-12	2022-08-04	Arcus Biosciences, Inc.	Treatment of oncogene-driven cancers
TW202102542A (en)	2019-03-19	2021-01-16	瓦爾希伯倫私人腫瘤研究基金會	Combination therapy for the treatment of cancer
JP7743309B2 (en)	2019-03-29	2025-09-24	アーカスバイオサイエンシズインコーポレイティド	Cancer treatment using identified adenosine fingerprints
AU2020253990A1 (en)	2019-04-02	2021-10-28	Bicycletx Limited	Bicycle toxin conjugates and uses thereof
BR112021019748A2 (en)	2019-04-05	2021-12-07	Kymera Therapeutics Inc	Stat degraders and their uses
US12012374B2 (en)	2019-05-13	2024-06-18	Bristol-Myers Squibb Company	Agonists of ROR GAMMAt
WO2020231766A1 (en)	2019-05-13	2020-11-19	Bristol-Myers Squibb Company	AGONISTS OF ROR GAMMAt
WO2020232051A1 (en)*	2019-05-15	2020-11-19	Biosion Inc.	Antibody binding csf-1r and use thereof
EP3976832A1 (en)	2019-05-30	2022-04-06	Bristol-Myers Squibb Company	Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy
JP2022534967A (en)	2019-05-30	2022-08-04	ブリストル－マイヤーズスクイブカンパニー	Multiple tumor gene signatures and their uses
CN114174537A (en)	2019-05-30	2022-03-11	百时美施贵宝公司	Cell localization features and combination therapies
MX2021014441A (en)	2019-05-31	2022-01-06	Ikena Oncology Inc	Tead inhibitors and uses thereof.
CN112300277A (en)*	2019-07-25	2021-02-02	苏州丁孚靶点生物技术有限公司	CSF1R antibodies, genes, vectors, host cells and CSF1R antagonists
US20220306630A1 (en)	2019-08-06	2022-09-29	Bristol-Myers Squibb Company	AGONISTS OF ROR GAMMAt
WO2021024020A1 (en)	2019-08-06	2021-02-11	Astellas Pharma Inc.	Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
AR119821A1 (en)	2019-08-28	2022-01-12	Bristol Myers Squibb Co	SUBSTITUTED PYRIDOPYRIMIDINOL COMPOUNDS USEFUL AS T-CELL ACTIVATORS
PH12022550605A1 (en)	2019-09-13	2023-09-25	Nimbus Saturn Inc	Hpk1 antagonists and uses thereof
BR112022004831A2 (en)	2019-09-19	2022-06-07	Bristol Myers Squibb Co	Antibodies that bind to seen at acidic pH
JP7712917B2 (en)	2019-09-26	2025-07-24	エフ．ホフマン－ラロシュアーゲー	Anti-CSF-1R antibody
KR20220103753A (en)	2019-11-19	2022-07-22	브리스톨-마이어스 스큅 컴퍼니	Compounds useful as inhibitors of helios proteins
ES3028099T3 (en)	2019-11-26	2025-06-18	Ikena Oncology Inc	Polymorphic carbazole derivatives and uses thereof
AU2020393854A1 (en)	2019-11-26	2022-06-09	Bristol-Myers Squibb Company	Salts/cocrystals of (R)-N-(4-chlorophenyl)-2-((1S,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide
BR112022011651A2 (en)	2019-12-17	2022-08-23	Kymera Therapeutics Inc	IRAK DEGRADATORS AND USES THEREOF
EP4076524A4 (en)	2019-12-17	2023-11-29	Kymera Therapeutics, Inc.	IRAQ DEGRADERS AND USES THEREOF
AU2020415377A1 (en)	2019-12-23	2022-08-18	Bristol-Myers Squibb Company	Substituted quinazolinyl compounds useful as T cell activators
CN115297931A (en)	2019-12-23	2022-11-04	凯麦拉医疗公司	SMARCA degraders and their uses
MX2022007369A (en)	2019-12-23	2022-07-12	Bristol Myers Squibb Co	SUBSTITUTED PIPERAZINE QUINOLINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS.
ES3013568T3 (en)	2019-12-23	2025-04-14	Bristol Myers Squibb Co	Substituted heteroaryl compounds useful as t cell activators
IL294270A (en)	2019-12-23	2022-08-01	Bristol Myers Squibb Co	Substituted piperazine derivatives are useful as t-cell activators
AR120823A1 (en)	2019-12-23	2022-03-23	Bristol Myers Squibb Co	SUBSTITUTED BICYCLIC COMPOUNDS USEFUL AS T-CELL ACTIVATORS
CN114835811B (en)*	2019-12-24	2024-03-26	宝船生物医药科技(上海)有限公司	anti-CSF 1R molecules and uses thereof
CN115210261B (en)	2020-01-07	2025-07-18	高诚生物医药公司	Anti-galectin-9 antibodies and uses thereof
EP4114529A1 (en)	2020-03-03	2023-01-11	PIC Therapeutics, Inc.	Eif4e inhibitors and uses thereof
KR20220151189A (en)	2020-03-09	2022-11-14	브리스톨-마이어스 스큅 컴퍼니	Antibodies to CD40 with enhanced agonist activity
US11407712B2 (en)	2020-03-19	2022-08-09	Arcus Biosciences, Inc.	Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2α
US20240424110A1 (en)	2020-03-19	2024-12-26	Kymera Therapeutics, Inc.	Mdm2 degraders and uses thereof
TW202140441A (en)	2020-03-23	2021-11-01	美商必治妥美雅史谷比公司	Substituted oxoisoindoline compounds
US20230272056A1 (en)	2020-04-09	2023-08-31	Merck Sharp & Dohme Llc	Affinity matured anti-lap antibodies and uses thereof
US20230192867A1 (en)	2020-05-15	2023-06-22	Bristol-Myers Squibb Company	Antibodies to garp
CR20220611A (en)	2020-06-02	2023-06-07	Arcus Biosciences Inc	ANTI-TIGIT ANTIBODIES
TW202210483A (en)	2020-06-03	2022-03-16	美商凱麥拉醫療公司	Crystalline forms of irak degraders
EP4161521A4 (en)	2020-06-03	2024-07-10	Kymera Therapeutics, Inc.	Deuterated irak degraders and uses thereof
WO2021257643A1 (en)	2020-06-17	2021-12-23	Arcus Biosciences, Inc.	Crystalline forms of a cd73 inhibitor and uses thereof
MX2023000197A (en)	2020-07-07	2023-02-22	BioNTech SE	THERAPEUTIC RNA FOR HPV POSITIVE CANCER.
CN116133692A (en)	2020-07-30	2023-05-16	凯麦拉医疗公司	Methods of treating mutant lymphomas
JP2023538906A (en)	2020-08-17	2023-09-12	バイシクルティーエクス・リミテッド	Bicyclic conjugates specific for nectin-4 and uses thereof
US20230303700A1 (en)	2020-08-31	2023-09-28	Bristol-Myers Squibb Company	Cell localization signature and immunotherapy
IL303376A (en)	2020-12-02	2023-08-01	Ikena Oncology Inc	TEAD inhibitors and their uses
WO2022120353A1 (en)	2020-12-02	2022-06-09	Ikena Oncology, Inc.	Tead inhibitors and uses thereof
WO2022120179A1 (en)	2020-12-03	2022-06-09	Bristol-Myers Squibb Company	Multi-tumor gene signatures and uses thereof
WO2022135666A1 (en)	2020-12-21	2022-06-30	BioNTech SE	Treatment schedule for cytokine proteins
WO2022135667A1 (en)	2020-12-21	2022-06-30	BioNTech SE	Therapeutic rna for treating cancer
TW202245808A (en)	2020-12-21	2022-12-01	德商拜恩迪克公司	Therapeutic rna for treating cancer
AU2021413371A1 (en)	2020-12-30	2023-07-13	Kymera Therapeutics, Inc.	Irak degraders and uses thereof
US20250186539A2 (en)	2021-01-11	2025-06-12	Bicycletx Limited	Methods for treating cancer
CA3206501A1 (en)	2021-02-02	2022-08-11	Shaun Abbott	Gpr84 antagonists and uses thereof
AU2022215844A1 (en)	2021-02-02	2023-09-14	Liminal Biosciences Limited	Gpr84 antagonists and uses thereof
US20240109899A1 (en)	2021-02-04	2024-04-04	Bristol-Myers Squibb Company	Benzofuran compounds as sting agonists
US12252488B2 (en)	2021-02-12	2025-03-18	Nimbus Saturn, Inc.	HPK1 antagonists and uses thereof
AU2022220869A1 (en)	2021-02-15	2023-08-24	Kymera Therapeutics, Inc.	Irak4 degraders and uses thereof
MX2023009527A (en)	2021-02-15	2023-08-24	Kymera Therapeutics Inc	Irak4 degraders and uses thereof.
JP2024509192A (en)	2021-03-05	2024-02-29	ニンバスサターン，インコーポレイテッド	HPK1 antagonists and their uses
US11918582B2 (en)	2021-03-15	2024-03-05	Rapt Therapeutics, Inc.	Pyrazole pyrimidine compounds and uses thereof
JP2024513011A (en)	2021-03-29	2024-03-21	ニンバスサターン，インコーポレイテッド	HPK1 antagonists and their uses
JP2024514530A (en)	2021-04-02	2024-04-02	ザリージェンツオブザユニバーシティオブカリフォルニア	Antibodies against truncated CDCP1 and uses thereof
JP2024515545A (en)	2021-04-05	2024-04-10	ブリストル－マイヤーズスクイブカンパニー	Pyridinyl-substituted oxoisoindoline compounds for cancer treatment
PL4320112T3 (en)	2021-04-06	2025-07-21	Bristol-Myers Squibb Company	Pyridinyl substituted oxoisoindoline compounds
IL307479A (en)	2021-04-09	2023-12-01	Nimbus Clio Inc	Modulators of CBL-B and their uses
EP4323066A1 (en)	2021-04-16	2024-02-21	Ikena Oncology, Inc.	Mek inhibitors and uses thereof
PH12023500023A1 (en)	2021-05-07	2024-03-11	Kymera Therapeutics Inc	Cdk2 degraders and uses thereof
JP2024521712A (en)	2021-05-21	2024-06-04	アーカスバイオサイエンシーズ，インコーポレーテッド	AXL Inhibitor Compounds
WO2022246177A1 (en)	2021-05-21	2022-11-24	Arcus Biosciences, Inc.	Axl compounds
MX2024000674A (en)	2021-07-13	2024-02-07	BioNTech SE	Multispecific binding agents against cd40 and cd137 in combination therapy for cancer.
JP2024534127A (en)	2021-08-25	2024-09-18	ピクセラピューティクス，インコーポレイテッド	eIF4E inhibitors and uses thereof
JP2024532276A (en)	2021-08-25	2024-09-05	ピクセラピューティクス，インコーポレイテッド	eIF4E inhibitors and uses thereof
TW202333802A (en)	2021-10-11	2023-09-01	德商拜恩迪克公司	Therapeutic rna for lung cancer
EP4423069A1 (en)	2021-10-29	2024-09-04	Arcus Biosciences, Inc.	Inhibitors of hif-2alpha and methods of use thereof
JP2024540080A (en)	2021-10-29	2024-10-31	カイメラセラピューティクス，インコーポレイテッド	IRAK4 degraders and their synthesis
WO2023114984A1 (en)	2021-12-17	2023-06-22	Ikena Oncology, Inc.	Tead inhibitors and uses thereof
TW202339738A (en)	2022-01-31	2023-10-16	美商凱麥拉醫療公司	Irak degraders and uses thereof
WO2023150186A1 (en)	2022-02-01	2023-08-10	Arvinas Operations, Inc.	Dgk targeting compounds and uses thereof
WO2023173057A1 (en)	2022-03-10	2023-09-14	Ikena Oncology, Inc.	Mek inhibitors and uses thereof
WO2023173053A1 (en)	2022-03-10	2023-09-14	Ikena Oncology, Inc.	Mek inhibitors and uses thereof
EP4493575A1 (en)	2022-03-18	2025-01-22	Bristol-Myers Squibb Company	Methods of isolating polypeptides
WO2023211889A1 (en)	2022-04-25	2023-11-02	Ikena Oncology, Inc.	Polymorphic compounds and uses thereof
KR20250006959A (en)	2022-05-02	2025-01-13	아르커스 바이오사이언시즈 인코포레이티드	Anti-TIGIT antibodies and uses thereof
JP2025519119A (en)	2022-05-25	2025-06-24	イケナオンコロジー，インコーポレイテッド	MEK inhibitors and their uses
EP4554680A1 (en)	2022-07-15	2025-05-21	Arcus Biosciences, Inc.	Inhibitors of hpk1 and methods of use thereof
WO2024020034A1 (en)	2022-07-20	2024-01-25	Arcus Biosciences, Inc.	Cbl-b inhibitors and methods of use thereof
CN120051456A (en)	2022-08-02	2025-05-27	里米诺生物科学有限公司	Substituted pyridone GPR84 antagonists and uses thereof
AU2023317740A1 (en)	2022-08-02	2025-03-13	Liminal Biosciences Limited	Heteroaryl carboxamide and related gpr84 antagonists and uses thereof
TW202415650A (en)	2022-08-02	2024-04-16	英商利米那生物科技有限公司	Aryl-triazolyl and related gpr84 antagonists and uses thereof
EP4568950A1 (en)	2022-08-08	2025-06-18	Bristol-Myers Squibb Company	Substituted tetrazolyl compounds useful as t cell activators
WO2024036101A1 (en)	2022-08-09	2024-02-15	Bristol-Myers Squibb Company	Tertiary amine substituted bicyclic compounds useful as t cell activators
EP4602041A1 (en)	2022-10-14	2025-08-20	Arcus Biosciences, Inc.	Hpk1 inhibitors and methods of use thereof
CN120091809A (en)	2022-10-20	2025-06-03	艾库斯生物科学有限公司	Lyophilized formulations of CD73 compounds
US20240208961A1 (en)	2022-11-22	2024-06-27	PIC Therapeutics, Inc.	Eif4e inhibitors and uses thereof
WO2024126457A1 (en)	2022-12-14	2024-06-20	Astellas Pharma Europe Bv	Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors
WO2024233360A1 (en)	2023-05-05	2024-11-14	Arcus Biosciences, Inc.	Cbl-b inhibitors and methods of use thereof
EP4511371A1 (en)	2023-05-08	2025-02-26	Bristol-Myers Squibb Company	Substituted phenyl oxazolone compounds
US20250011441A1 (en)	2023-05-17	2025-01-09	Syndax Pharmaceuticals, Inc.	Methods of treating chronic graft-versus-host disease-related bronchiolitis obliterans syndrome using an anti-colony stimulating factor 1 receptor antibody
WO2024243502A1 (en)	2023-05-25	2024-11-28	Arcus Biosciences, Inc.	Cbl-b inhibitors and methods of use thereof
WO2024249540A1 (en)	2023-05-31	2024-12-05	Bristol-Myers Squibb Company	Substituted oxazolone compound for decreasing levels of ikzf1-4 proteins
WO2024254227A1 (en)	2023-06-07	2024-12-12	Bristol-Myers Squibb Company	Spirocyclic substituted oxoisoindolinyl piperidine-2,6-dione compound
WO2024263853A1 (en)	2023-06-23	2024-12-26	Bristol-Myers Squibb Company	Substituted oxoisoindolinyl piperidine-2,6-dione compound as anticancer agent
US20250059164A1 (en)	2023-06-23	2025-02-20	Kymera Therapeutics, Inc.	Irak degraders and uses thereof
WO2025030002A2 (en)	2023-08-02	2025-02-06	Arvinas Operations, Inc.	Dgk targeting compounds and uses thereof
WO2025038763A1 (en)	2023-08-15	2025-02-20	Bristol-Myers Squibb Company	Ceramic hydroxyapatite chromatography flow through method
WO2025049840A1 (en)	2023-09-02	2025-03-06	Bristol-Myers Squibb Company	Substituted phenyl oxooxazolyl piperidine dione compounds
US20250084056A1 (en)	2023-09-13	2025-03-13	Bristol-Myers Squibb Company	Substituted oxoisoindolinyl piperidine-2,6-dione compounds
WO2025076299A1 (en)	2023-10-06	2025-04-10	Arcus Biosciences, Inc.	Cbl-b inhibitors and methods of use thereof
WO2025096490A1 (en)	2023-10-31	2025-05-08	Bristol-Myers Squibb Company	Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096505A1 (en)	2023-10-31	2025-05-08	Bristol-Myers Squibb Company	Ubiquitin specific processing protease 1 (usp1) compounds
US20250145590A1 (en)	2023-10-31	2025-05-08	Bristol-Myers Squibb Company	Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096488A1 (en)	2023-10-31	2025-05-08	Bristol-Myers Squibb Company	Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096487A1 (en)	2023-10-31	2025-05-08	Bristol-Myers Squibb Company	Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096494A1 (en)	2023-10-31	2025-05-08	Bristol-Myers Squibb Company	Ubiquitin specific processing protease 1 (usp1) compounds
WO2025121445A1 (en)	2023-12-08	2025-06-12	Astellas Pharma Inc.	Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025120866A1 (en)	2023-12-08	2025-06-12	Astellas Pharma Inc.	Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025120867A1 (en)	2023-12-08	2025-06-12	Astellas Pharma Inc.	Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
EP0382781B1 (en)	1987-10-23	1993-09-29	Genetics Institute, Inc.	Composition for treating cancers characterized by over-expression of the c-fms proto-oncogene
GB8823869D0 (en)	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US6673986B1 (en)	1990-01-12	2004-01-06	Abgenix, Inc.	Generation of xenogeneic antibodies
US6713610B1 (en)	1990-01-12	2004-03-30	Raju Kucherlapati	Human antibodies derived from immunized xenomice
US6255458B1 (en)	1990-08-29	2001-07-03	Genpharm International	High affinity human antibodies and human antibodies against digoxin
US5877397A (en)	1990-08-29	1999-03-02	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US5874299A (en)	1990-08-29	1999-02-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en)	1990-08-29	2001-10-09	Genpharm International	Transgenic non-human animals for producing heterologous antibodies
EP0668914B1 (en)	1992-06-09	2000-08-16	Chiron Corporation	Crystallization of m-csf
US20020193575A1 (en)*	1993-09-07	2002-12-19	Smithkline Beecham P.L.C.	Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US6972323B1 (en)*	1997-04-01	2005-12-06	Sankyo Company, Limited	Anti-Fas antibodies
US6342220B1 (en)	1997-08-25	2002-01-29	Genentech, Inc.	Agonist antibodies
WO1999029345A1 (en)	1997-12-05	1999-06-17	La Jolla Institute For Experimental Medicine	Inhibition of tumor growth by macrophage intervention
EP1125584A4 (en)	1998-10-30	2005-01-12	Takeda Chemical Industries Ltd	Betacellulin protein-containing preparations
EP1223980B1 (en)	1999-10-28	2003-05-21	Hofbauer, Reinhold	Use of csf-1 inhibitors
AU1759501A (en)	1999-11-08	2001-06-06	Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The	Method of treating a viral infection using antagonists of macrophage colony stimulating factor
US7108852B2 (en)	2000-03-20	2006-09-19	Warner-Lambert Company Llc	Methods of treating inflammation using antibodies to M-CSF
US7455836B2 (en)	2000-05-08	2008-11-25	The University Of Melbourne	Method of treatment and agents useful for same
US6773895B2 (en)	2000-09-01	2004-08-10	Boehringer Ingelheim Pharma Kg	Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases
US7247618B2 (en)	2001-04-30	2007-07-24	Tripathi Rajavashisth	Methods for inhibiting macrophage colony stimulating factor and c-FMS-dependent cell signaling
DE60233509D1 (en)	2001-06-20	2009-10-08	Fibron Ltd	FGFR3 BLOCKING ANTIBODIES, METHOD OF SCREENING THEREOF AND USES THEREOF
KR100708398B1 (en)	2002-03-22	2007-04-18	(주) 에이프로젠	Humanized antibody and process for preparing same
CN1787837A (en)	2002-11-15	2006-06-14	希龙公司	Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
US7807389B2 (en)	2003-03-14	2010-10-05	University Of Rochester	Methods and compositions related to joint inflammation diseases
AR045563A1 (en)*	2003-09-10	2005-11-02	Warner Lambert Co	ANTIBODIES DIRECTED TO M-CSF
EP2330201B1 (en)	2003-10-22	2017-04-05	Keck Graduate Institute	Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy
GB0325836D0 (en)	2003-11-05	2003-12-10	Celltech R&D Ltd	Biological products
WO2005070447A2 (en)	2004-01-21	2005-08-04	Chiron Corporation	M-csf muteins and uses thereof
EP1745073A2 (en)	2004-05-14	2007-01-24	Receptor Biologix, Inc.	Cell surface receptor isoforms and methods of identifying and using the same
WO2006012451A2 (en)	2004-07-22	2006-02-02	Five Prime Therapeutics, Inc.	Compositions and methods of use for mgd-csf in disease treatment
WO2006076288A2 (en)	2005-01-11	2006-07-20	Five Prime Therapeutics, Inc.	Dna constructs for long-term expression of intravascularly injected naked dna
EP1841874B1 (en)	2005-01-27	2010-01-06	Five Prime Therapeutics, Inc.	Leader sequences for directing secretion of polypeptides and methods for production thereof
US8003108B2 (en)*	2005-05-03	2011-08-23	Amgen Inc.	Sclerostin epitopes
US20070166788A1 (en)	2005-11-10	2007-07-19	Pei Jin	Methods for production of receptor and ligand isoforms
WO2007075933A2 (en)	2005-12-21	2007-07-05	Cell Signaling Technology, Inc.	Translocation and mutant csf1r kinase in human leukemia
WO2007120252A2 (en)	2005-12-22	2007-10-25	Novartis Ag	Soluble human m-csf receptor and uses thereof
CN101534858A (en)	2006-01-05	2009-09-16	诺华有限公司	Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
EP2097450A2 (en)	2006-11-10	2009-09-09	Amgen Inc.	Antibody-based diagnostics and therapeutics
US20100266528A1 (en)	2006-11-17	2010-10-21	Biogen Idec Ma Inc.	Systemic Administration of Colony Stimulating Factors to Treat Amyloid Associated Disorders
DE602008004296D1 (en)*	2007-02-14	2011-02-17	Vaccinex Inc	HUMANIZED ANTI-CD100 ANTIBODIES
WO2008124858A2 (en)	2007-04-11	2008-10-23	F-Star Biotechnologische Forschungs- Und Entwicklungsges. M.B.H.	Targeted receptor
US20100298217A1 (en)	2007-05-30	2010-11-25	Evan Richard Stanley	Csf-1r mutants
NZ583282A (en)	2007-08-21	2012-09-28	Amgen Inc	Human c-fms antigen binding proteins
US7981415B2 (en)	2007-09-07	2011-07-19	Cisthera, Inc.	Humanized PAI-1 antibodies
CA2702699A1 (en)	2007-10-18	2009-04-23	Novartis Ag	Csf-1r inhibitors compositions, and mthods of use
AU2008318656A1 (en)	2007-10-31	2009-05-07	Janssen Pharmaceutica N.V.	Biomarker for assessing response to FMS treatment
US20110262425A1 (en)	2007-12-12	2011-10-27	National Cancer Center	Therapeutic agent for mll leukemia and moz leukemia of which molecular target is m-csf receptor, and use thereof
MX2010009894A (en)*	2008-03-14	2011-02-22	Transgene Sa	Antibody against the csf-1 r.
US8470977B2 (en)	2008-03-14	2013-06-25	Transgene S.A.	Antibody against the CSF-1R
WO2010062399A2 (en)	2008-11-26	2010-06-03	Five Prime Therapeutics, Inc.	Csf1r extracellular domain fusion molecules and treatments using same
US8183207B2 (en)	2008-11-26	2012-05-22	Five Prime Therapeutics, Inc.	Treatment of osteolytic disorders and cancer using CSF1R extracellular domain fusion molecules
RU2565541C2 (en)	2009-12-10	2015-10-20	Ф.Хоффманн-Ля Рош Аг	Antibodies primarily binding to extracellular domain 4 of human csf-1r, and using them
KR101647871B1 (en)	2010-03-05	2016-08-11	에프. 호프만-라 로슈 아게	Antibodies against human csf-1r and uses thereof
BR112012020372A8 (en)	2010-03-05	2018-01-02	Hoffmann La Roche	human csf-1r binding antibody, pharmaceutical composition, nucleic acid, expression vectors, host cell and method for producing a recombinant antibody
AR080698A1 (en)	2010-04-01	2012-05-02	Imclone Llc	ANTIBODY OR FRAGMENT OF THE SAME THAT SPECIFICALLY LINKS THE VARIOUS OF HUMAN CSF -1R, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, ITS USE FOR THE MANUFACTURE OF A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF CANCER AND METHOD TO DETERMINE IF A BASED SUBJECT MATTER AND
SG10201911345WA (en)	2010-05-04	2020-01-30	Five Prime Therapeutics Inc	Antibodies that bind csf1r
WO2012082573A1 (en)	2010-12-13	2012-06-21	Novartis Ag	Predictive methods and methods of treating arthritis using il-17 antagonists
CA2852800A1 (en)	2011-10-21	2013-04-25	Inserm (Institut National De La Sante Et De La Recherche Medicale)	A m-dc8+ monocyte depleting agent for the prevention or the treatment of a condition associated with a chronic hyperactivation of the immune system
RU2639553C2 (en)	2011-10-21	2017-12-21	Трансжене Са	Macrophage activation modulation
US20130302322A1 (en)	2012-05-11	2013-11-14	Five Prime Therapeutics, Inc.	Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
HK1208233A1 (en)	2012-05-11	2016-02-26	戊瑞治疗有限公司	Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
US20140079699A1 (en)	2012-08-31	2014-03-20	Five Prime Therapeutics, Inc.	Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)

2011
- 2011-05-04SGSG10201911345WApatent/SG10201911345WA/enunknown
- 2011-05-04DKDK11778283.9Tpatent/DK2566517T3/enactive
- 2011-05-04ESES18151214Tpatent/ES2820517T3/enactiveActive
- 2011-05-04CNCN201610842693.8Apatent/CN106977603B/enactiveActive
- 2011-05-04MXMX2015007635Apatent/MX355418B/enunknown
- 2011-05-04TWTW107143066Apatent/TWI713942B/ennot_activeIP Right Cessation
- 2011-05-04TRTR2019/00368Tpatent/TR201900368T4/enunknown
- 2011-05-04AUAU2011248083Apatent/AU2011248083B2/ennot_activeCeased
- 2011-05-04SGSG2012079133Apatent/SG185035A1/enunknown
- 2011-05-04CACA2797399Apatent/CA2797399C/enactiveActive
- 2011-05-04KRKR1020207011504Apatent/KR20200044999A/ennot_activeCeased
- 2011-05-04KRKR1020187006772Apatent/KR102105776B1/enactiveActive
- 2011-05-04TWTW105113540Apatent/TWI595008B/ennot_activeIP Right Cessation
- 2011-05-04WOPCT/US2011/035231patent/WO2011140249A2/enactiveApplication Filing
- 2011-05-04BRBR112012027994-7Apatent/BR112012027994B1/ennot_activeIP Right Cessation
- 2011-05-04EPEP18151214.6Apatent/EP3357510B1/enactiveActive
- 2011-05-04EAEA201291161Apatent/EA036336B1/ennot_activeIP Right Cessation
- 2011-05-04PTPT11778283Tpatent/PT2566517T/enunknown
- 2011-05-04EPEP20182161.8Apatent/EP3943154A1/ennot_activeWithdrawn
- 2011-05-04HRHRP20190047TTpatent/HRP20190047T1/enunknown
- 2011-05-04TWTW109142917Apatent/TW202112827A/enunknown
- 2011-05-04NZNZ712765Apatent/NZ712765A/ennot_activeIP Right Cessation
- 2011-05-04KRKR1020127031635Apatent/KR101838698B1/enactiveActive
- 2011-05-04CNCN202011184552.4Apatent/CN112480256A/enactivePending
- 2011-05-04HUHUE11778283Apatent/HUE042898T2/enunknown
- 2011-05-04CNCN201610842863.2Apatent/CN107011438B/enactiveActive
- 2011-05-04PLPL11778283Tpatent/PL2566517T3/enunknown
- 2011-05-04ESES11778283Tpatent/ES2706412T3/enactiveActive
- 2011-05-04SMSM20190074Tpatent/SMT201900074T1/enunknown
- 2011-05-04CNCN201180022404.5Apatent/CN103179985B/enactiveActive
- 2011-05-04LTLTEP11778283.9Tpatent/LT2566517T/enunknown
- 2011-05-04SGSG10201604798SApatent/SG10201604798SA/enunknown
- 2011-05-04TWTW100115607Apatent/TWI542361B/ennot_activeIP Right Cessation
- 2011-05-04RSRS20190025Apatent/RS58211B1/enunknown
- 2011-05-04EPEP11778283.9Apatent/EP2566517B1/enactiveActive
- 2011-05-04MXMX2017015045Apatent/MX378336B/enunknown
- 2011-05-04NZNZ626610Apatent/NZ626610A/ennot_activeIP Right Cessation
- 2011-05-04SISI201131627Tpatent/SI2566517T1/enunknown
- 2011-05-04TWTW106117413Apatent/TWI651331B/enactive
- 2011-05-04JPJP2013509230Apatent/JP6008842B2/enactiveActive
- 2011-05-04USUS13/100,990patent/US8206715B2/enactiveActive
- 2011-05-04MXMX2012012790Apatent/MX2012012790A/enactiveIP Right Grant
- 2011-05-04NZNZ603193Apatent/NZ603193A/ennot_activeIP Right Cessation
2012
- 2012-05-04USUS13/464,503patent/US8747845B2/enactiveActive
- 2012-10-23ILIL222629Apatent/IL222629B/enactiveIP Right Grant
2014
- 2014-04-30USUS14/266,209patent/US9200075B2/enactiveActive
2015
- 2015-05-07AUAU2015202477Apatent/AU2015202477C1/ennot_activeCeased
- 2015-10-27USUS14/924,568patent/US9695243B2/enactiveActive
2016
- 2016-03-31JPJP2016071180Apatent/JP6196347B2/enactiveActive
- 2016-09-29USUS15/279,853patent/US9957327B2/enactiveActive
- 2016-11-22AUAU2016262662Apatent/AU2016262662B2/ennot_activeCeased
2017
- 2017-08-17JPJP2017157498Apatent/JP6529552B2/enactiveActive
- 2017-11-08ILIL255524Apatent/IL255524B/enactiveIP Right Grant
2018
- 2018-02-25ILIL257712Apatent/IL257712B/enactiveIP Right Grant
- 2018-03-26USUS15/935,621patent/US10562970B2/enactiveActive
2019
- 2019-01-14CYCY191100027Tpatent/CY1121102T1/enunknown
- 2019-02-01AUAU2019200691Apatent/AU2019200691B2/ennot_activeCeased
- 2019-05-14JPJP2019091364Apatent/JP2019180413A/enactivePending
2020
- 2020-01-08USUS16/737,217patent/US11186646B2/enactiveActive
2021
- 2021-09-14JPJP2021149042Apatent/JP2022008382A/ennot_activeWithdrawn
- 2021-10-28USUS17/513,109patent/US20220153851A1/ennot_activeAbandoned
2023
- 2023-08-16JPJP2023132563Apatent/JP2023144055A/ennot_activeWithdrawn

Publication number	Publication date
SMT201900074T1 (en)	2019-02-28
US9957327B2 (en)	2018-05-01
PL2566517T3 (en)	2019-04-30
US20140322757A1 (en)	2014-10-30
JP2023144055A (en)	2023-10-06
RS58211B1 (en)	2019-03-29
EA201291161A3 (en)	2013-10-30
IL222629B (en)	2020-10-29
MX2012012790A (en)	2013-02-15
TW201809002A (en)	2018-03-16
US9695243B2 (en)	2017-07-04
SG185035A1 (en)	2012-11-29
JP6008842B2 (en)	2016-10-19
EP3357510A1 (en)	2018-08-08
CN103179985B (en)	2016-10-26
BR112012027994A2 (en)	2017-03-21
KR20130108078A (en)	2013-10-02
NZ712765A (en)	2017-01-27
CN107011438B (en)	2020-11-20
US20160046719A1 (en)	2016-02-18
EA201291161A2 (en)	2013-04-30
EP2566517B1 (en)	2018-10-24
TWI651331B (en)	2019-02-21
TR201900368T4 (en)	2019-02-21
SI2566517T1 (en)	2019-01-31
NZ626610A (en)	2015-11-27
JP6529552B2 (en)	2019-06-12
CY1121102T1 (en)	2019-12-11
MX378336B (en)	2025-03-10
JP2013535952A (en)	2013-09-19
EP3357510B1 (en)	2020-08-05
EP3943154A1 (en)	2022-01-26
TW202112827A (en)	2021-04-01
BR112012027994B1 (en)	2021-10-13
KR102105776B1 (en)	2020-04-28
WO2011140249A2 (en)	2011-11-10
AU2011248083B2 (en)	2015-09-10
JP2017221215A (en)	2017-12-21
HUE042898T2 (en)	2019-07-29
US9200075B2 (en)	2015-12-01
US20120219524A1 (en)	2012-08-30
US10562970B2 (en)	2020-02-18
ES2820517T3 (en)	2021-04-21
AU2016262662B2 (en)	2018-11-01
AU2015202477B2 (en)	2017-03-09
AU2019200691A1 (en)	2019-02-21
CN106977603B (en)	2020-11-27
DK2566517T3 (en)	2019-01-07
KR101838698B1 (en)	2018-03-16
TW201925232A (en)	2019-07-01
MX355418B (en)	2018-04-18
IL257712B (en)	2020-07-30
CN107011438A (en)	2017-08-04
TWI595008B (en)	2017-08-11
WO2011140249A3 (en)	2013-08-15
EP2566517A4 (en)	2015-05-20
US20180215830A1 (en)	2018-08-02
US11186646B2 (en)	2021-11-30
IL222629A0 (en)	2012-12-31
US8206715B2 (en)	2012-06-26
KR20200044999A (en)	2020-04-29
US20220153851A1 (en)	2022-05-19
CA2797399A1 (en)	2011-11-10
LT2566517T (en)	2019-01-10
US8747845B2 (en)	2014-06-10
US20200223931A1 (en)	2020-07-16
IL255524B (en)	2018-10-31
SG10201604798SA (en)	2016-07-28
JP2016193898A (en)	2016-11-17
TW201641517A (en)	2016-12-01
TWI713942B (en)	2020-12-21
PT2566517T (en)	2019-01-24
EA036336B1 (en)	2020-10-28
US20110274683A1 (en)	2011-11-10
AU2015202477C1 (en)	2017-11-16
JP2019180413A (en)	2019-10-24
CA2797399C (en)	2021-03-02
ES2706412T3 (en)	2019-03-28
JP2022008382A (en)	2022-01-13
AU2016262662A1 (en)	2016-12-08
CN106977603A (en)	2017-07-25
HRP20190047T1 (en)	2019-02-22
CN112480256A (en)	2021-03-12
AU2011248083A1 (en)	2012-11-15
TW201206467A (en)	2012-02-16
TWI542361B (en)	2016-07-21
IL257712A (en)	2018-04-30
KR20180028560A (en)	2018-03-16
CN103179985A (en)	2013-06-26
AU2019200691B2 (en)	2021-01-21
NZ603193A (en)	2014-07-25
US20170081415A1 (en)	2017-03-23
JP6196347B2 (en)	2017-09-13
EP2566517A2 (en)	2013-03-13
AU2015202477A1 (en)	2015-05-28
IL255524A (en)	2018-01-31

Publication	Publication Date	Title
IL257712B (en)	2020-07-30	Antibodies that bind csf1r
PL2581113T3 (en)	2018-11-30	Anti-tim-3 antibody
HRP20180952T1 (en)	2018-07-27	Anti-dll3 antibody
ZA201209004B (en)	2013-08-28	Anti-fgfr2 antibodies
GB201000467D0 (en)	2010-02-24	Antibodies
PL2616489T3 (en)	2017-07-31	Anti-hutnfr1 antibody
IL221371A0 (en)	2012-10-31	Anti-lrp6 antibodies
ZA201208290B (en)	2013-07-31	Anti-erbb3 antibodies
GB201000064D0 (en)	2010-02-17	Humanized antibodies
PL2603528T3 (en)	2017-07-31	Fab-glycosylated antibodies
GB201020738D0 (en)	2011-01-19	Antibodies
ZA201302459B (en)	2014-01-29	Antibodies
GB201002238D0 (en)	2010-03-31	Antibodies
GB201007957D0 (en)	2010-06-30	Antibody
GB201017780D0 (en)	2010-12-01	Antibody
GB201020751D0 (en)	2011-01-19	Antibodies
GB201005062D0 (en)	2010-05-12	Antibodies

Movatterモバイル変換

SG10201911345WA - Antibodies that bind csf1r - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (1)

Publications (1)

Family

ID=44902080

Family Applications (3)

Family Applications After (2)

Country Status (27)

Families Citing this family (296)

Family Cites Families (65)

Also Published As

Similar Documents